Co-Diagnostics, Inc. (0A50.L)
| Previous close | 1.1700 |
| Open | 1.0900 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.0900 - 1.1590 |
| 52-week range | 0.9980 - 2.9780 |
| Volume | |
| Avg. volume | 3,139 |
| Market cap | N/A |
| Beta (5Y monthly) | -0.83 |
| PE ratio (TTM) | 0.01 |
| EPS (TTM) | 1.3120 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCo-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Executive
- PR Newswire
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's vector control technology will expand to the 15th U.S. state following an installation in Nevada next week.
- PR Newswire
Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21.
